Kuros Biosciences Raises 2026 Annual Guidance After Nine-Month Sales Rise 40%
Kuros Biosciences reported a 40% year-over-year increase in sales for the first nine months of 2026 and increased its annual guidance.
Story updates
05:01:40 AM UTC
SquawkNews
Kuros Biosciences increased its 2026 full-year guidance for revenue growth and adjusted EBITDA after reporting a 40% YoY sales rise in the first nine months of 2026.Material DetailsContext by AI AnalystThis is a mid-cycle confirmation of accelerating growth and improving profitability, reinforced b…
Ad hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences increases 2026 annual guidanceThe company reports 40% year-over-year increase in sales in the first nine months of 2026Schlieren (Zurich), Switzerland, October 15, 2026 — Kuros Biosciences (“Kuros” or the “Company”…